Syed Haider

List of Publications by Year
in descending order

40 papers	4,799 citations	331670 21 h-index	289244 40 g-index
42 all docs	42 docs citations	42 times ranked	11348 citing authors

#	Article	IF	Citations
1	The Molecular Taxonomy of Primary Prostate Cancer. Cell, 2015, 163, 1011-1025.	28.9	2,435
2	The BioMart community portal: an innovative alternative to large, centralized data repositories. Nucleic Acids Research, 2015, 43, W589-W598.	14.5	682
3	A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1. Genes and Development, 2017, 31, 353-369.	5.9	168
4	Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nature Communications, 2021, 12, 3636.	12.8	159
5	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine, 2018, 31, 182-189.	6.1	132
6	Sex Differences in Cancer Driver Genes and Biomarkers. Cancer Research, 2018, 78, 5527-5537.	0.9	108
7	Capture Hi-C identifies putative target genes at 33 breast cancer risk loci. Nature Communications, 2018, 9, 1028.	12.8	98
8	Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction. Genome Medicine, 2013, 5, 29.	8.2	96
9	Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12452-12461.	7.1	86
10	RASSF1A uncouples Wnt from Hippo signalling and promotes YAP mediated differentiation via p73. Nature Communications, 2018, 9, 424.	12.8	72
11	Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. Genome Biology, 2016, 17, 140.	8.8	67
12	BPG: Seamless, automated and interactive visualization of scientific data. BMC Bioinformatics, 2019, 20, 42.	2.6	64
13	Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer. Nature, 2020, 585, 447-452.	27.8	63
14	Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. British Journal of Cancer, 2021, 124, 494-505.	6.4	62
15	Sex differences in oncogenic mutational processes. Nature Communications, 2020, 11, 4330.	12.8	60
16	Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget, 2014, 5, 5934-5949.	1.8	59
17	IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer. British Journal of Cancer, 2017, 117, 1600-1606.	6.4	35
18	Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis. Nature Communications, 2021, 12, 3516.	12.8	35

#	Article	IF	Citations
19	ISOpureR: an R implementation of a computational purification algorithm of mixed tumour profiles. BMC Bioinformatics, 2015, 16, 156.	2.6	30
20	Pathway-based subnetworks enable cross-disease biomarker discovery. Nature Communications, 2018, 9, 4746.	12.8	30
21	Age influences on the molecular presentation of tumours. Nature Communications, 2022, 13, 208.	12.8	26
22	Systematic Assessment of Tumor Purity and Its Clinical Implications. JCO Precision Oncology, 2020, 4, 995-1005.	3.0	23
23	Adaptation to HIF1α Deletion in Hypoxic Cancer Cells by Upregulation of GLUT14 and Creatine Metabolism. Molecular Cancer Research, 2019, 17, 1531-1544.	3.4	22
24	A bedr way of genomic interval processing. Source Code for Biology and Medicine, 2016, 11, 14.	1.7	21
25	3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers. Molecular Cancer Therapeutics, 2019, 18, 376-388.	4.1	17
26	Landscape of transcriptomic interactions between breast cancer and its microenvironment. Nature Communications, 2019, 10, 3116.	12.8	16
27	Predicting the clinical outcome of oral potentially malignant disorders using transcriptomic-based molecular pathology. British Journal of Cancer, 2021, 125, 413-421.	6.4	16
28	Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 161.	8.6	16
29	ADGRL4/ELTD1 Silencing in Endothelial Cells Induces ACLY and SLC25A1 and Alters the Cellular Metabolic Profile. Metabolites, 2019, 9, 287.	2.9	14
30	Characterisation of the Stromal Microenvironment in Lobular Breast Cancer. Cancers, 2022, 14, 904.	3.7	13
31	Identifying high-confidence capture Hi-C interactions using CHiCANE. Nature Protocols, 2021, 16, 2257-2285.	12.0	11
32	Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma. Cancers, 2021, 13, 3854.	3.7	10
33	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	6.2	6
34	ELTD1 Activation Induces an Endothelial-EMT Transition to a Myofibroblast Phenotype. International Journal of Molecular Sciences, 2021, 22, 11293.	4.1	6
35	Functional annotation of breast cancer risk loci: current progress and future directions. British Journal of Cancer, 2022, 126, 981-993.	6.4	6
36	Liver glycogen phosphorylase is upregulated in glioblastoma and provides a metabolic vulnerability to high dose radiation. Cell Death and Disease, 2022, 13, .	6.3	6

#	Article	IF	Citations
37	The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing. Journal of Clinical Medicine, 2021, 10, 215.	2.4	5
38	Assessment of the Molecular Heterogeneity of E-Cadherin Expression in Invasive Lobular Breast Cancer. Cancers, 2022, 14, 295.	3.7	5
39	Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency. Communications Biology, 2021, 4, 1270.	4.4	4
40	Developing and validating a multivariable predictive biomarker for treatment selection for oropharyngeal squamous cell carcinoma: The PREDICTR-OPC study.. Journal of Clinical Oncology, 2017, 35, 6004-6004.	1.6	3